2. Academic Validation
  3. Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression

Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression

  • Mol Cancer Ther. 2020 Mar;19(3):755-764. doi: 10.1158/1535-7163.MCT-19-0947.
Shweta Joshi  # 1,  Kevin X Liu 2,  Muamera Zulcic 2,  Alok R Singh 2,  Dylan Skola 3,  Christopher K Glass 3,  P Dominick Sanders 4,  Andrew B Sharabi 4,  Timothy V Pham 2 5,  Pablo Tamayo 5,  Daniel Shiang 2,  Huy Q Dinh 6,  Catherine C Hedrick 6,  Guillermo A Morales 7,  Joseph R Garlich 7,  Donald L Durden  # 1 7
Affiliations

Affiliations

  • 1 UCSD Department of Pediatrics, University of California, San Diego, San Diego, California. shjoshi@ucsd.edu durden@signalrx.com.
  • 2 UCSD Department of Pediatrics, University of California, San Diego, San Diego, California.
  • 3 UCSD School of Medicine, University of California, San Diego, San Diego, California.
  • 4 Moores Cancer Center, Department of Radiation Medicine and Applied Sciences, University of California, San Diego, San Diego, California.
  • 5 Office of Cancer Genomics, University of California, San Diego, San Diego, California.
  • 6 La Jolla Institute of Allergy and Immunology, La Jolla, California.
  • 7 SignalRx Pharmaceuticals, Omaha, Nebraska.
  • # Contributed equally.
PMID: 31974273 DOI: 10.1158/1535-7163.MCT-19-0947
Abstract

Macrophages (MΦ) play a critical role in tumor growth, immunosuppression, and inhibition of adaptive immune responses in Cancer. Hence, targeting signaling pathways in MΦs that promote tumor immunosuppression will provide therapeutic benefit. PI3Kγ has been recently established by our group and Others as a novel immuno-oncology target. Herein, we report that an MΦ Syk-PI3K axis drives polarization of immunosuppressive MΦs that establish an immunosuppressive tumor microenvironment in in vivo syngeneic tumor models. Genetic or pharmacologic inhibition of Syk and/or PI3Kγ in MΦs promotes a proinflammatory MΦ phenotype, restores CD8+ T-cell activity, destabilizes HIF under hypoxia, and stimulates an antitumor immune response. Assay for transposase-accessible Chromatin using Sequencing (ATAC-seq) analyses on the bone marrow-derived macrophages (BMDM) show that inhibition of Syk kinase promotes activation and binding of NF-κB motif in SykMC-KO BMDMs, thus stimulating immunostimulatory transcriptional programming in MΦs to suppress tumor growth. Finally, we have developed in silico the "first-in-class" dual Syk/PI3K Inhibitor, SRX3207, for the combinatorial inhibition of Syk and PI3K in one small molecule. This chemotype demonstrates efficacy in multiple tumor models and represents a novel combinatorial approach to activate antitumor immunity.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-136198
    98.50%, Syk/PI3K 抑制剂
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z